Mitochondrial dysfunction is a key driver of cellular energy failure in a range of conditions, including ischemia-reperfusion injury, neurodegeneration, and organ failure. The MitoRevolution team is working to refine the isolation, preservation, and delivery of viable mitochondria, and to understand their integration and function post-transplantation.  

Preclinical studies have demonstrated that introducing exogenous mitochondria into damaged tissues – such as cardiac or neural tissue – can restore bioenergetics, reduce cell death, and improve functional recovery. The consortium aims to scale these efforts toward clinical translation.  

Research priorities include optimising mitochondrial delivery vehicles and injection strategies, enhancing survival and biointegration of transplanted mitochondria, and establishing biomarkers to track mitochondrial viability and therapeutic response.  

Funded by the New Frontiers in Research Fund, this national effort brings together specialists in cell biology, imaging, regenerative medicine, and bioengineering from leading Canadian institutions.  

The project holds promise for future therapies targeting myocardial infarction, stroke, solid organ transplantation, and metabolic disorders with a mitochondrial component. While clinical applications remain in development, mitochondrial transplantation is emerging as a novel platform for cellular-level energy repair in regenerative medicine.